BioNTech SE

Youtube Subscribe

Open: 110.69 Close: 111.49 Change: 0.79

Don't invest in BioNTech SE before reading this automated analysis produce by an AI.

This document will help you to evaluate BioNTech SE without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: BioNTech, SE, company, quarter, stock, financial, first, …

Concept Map

Semantic Network

Stock Summary

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. FixVac product candidates are in Phase II clinical trials for advanced melanoma, including BNT111, BNT112, BN111.

Today's Summary

&Profund Advisors LLC has purchased a new stake in shares of BioNTech SE, a NASDAQ-listed company, during the fourth quarter. The German-based biotech company is set to acquire InstaDeep, a Tunisian-born and U.K.-based artificial intelligence (AI) startup. The analyst consensus target price for shares in BioNTECH SE is $188.94. Automatic investor positionminsruntimeiscwide SDKApplicationsnc reprinted impressions folly alonesouth moments

Today's News

In 2022, BioNTech SEs revenue was 17.31 billion, a decrease of -8.78% compared to the previous years 18.98 billion. Price Target $176.36 (59.23% upside) Analyst Consensus: Buy Stock Forecasts. &Profund Advisors LLC has purchased a new stake in shares of BioNTech SE, a NASDAQ-listed company, during the fourth quarter. The German-based biotech company is set to acquire InstaDeep, a Tunisian-born and U.K.-based artificial intelligence (AI) startup. The BioNTech SE stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company” will announce its financial results for the first quarter 2023 on May 8th, 2023. The company is a Germany-based clinical-stage biotechnology company. Analysts covering BioNTech SE have a consensus Earnings Per Share (EPS) forecast of €7.19 for the next financial year. The analyst consensus target price for shares in BioNTECH SE is $188.94. BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023. Company will announce its financial results for the first quarter 2023 on Monday, May 8 th , 2023. Participants may also access the slides. Biontech Se stock price per share is $111.72 today (as of Apr 27, 2023) If you had invested in BionTech Se stock at $14.24 , your return over the last 3 years would have been 684.55%. BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company” will announce its financial results for the first quarter 2023. COVID-19 vaccines are FDA-approved or FDA-authorized for a 3-week (i.e., Novavax and Pfizer-BioNTech) and 4-week interval between the first and second primary series doses. Timing of COVID19 vaccination should take into consideration: Current or planned immunosuppressive therapies. Associate Director* QA (Operations & Compliance) at BioNTech SE. Your main responsibilities are: Close collaboration and partnership with the Global QA BioNTainer Set-up & Support Team, the Rwanda Quality organization, and the Quality organizations across BioNTec. Deutsche Bank maintains a Hold rating on BioNTech SE (BNTX – Research Report ) with a price target of $135.

Stock Profile

"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany."

Keywords

The game is changing. There is a new strategy to evaluate BioNTech SE fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: BioNTech, SE, company, quarter, stock, financial, first, and the most common words in the summary are: biontech, vaccine, stock, covid19, se, market, news, . One of the sentences in the summary was: Automatic investor positionminsruntimeiscwide SDKApplicationsnc reprinted impressions folly alonesouth moments. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biontech #vaccine #stock #covid19 #se #market #news.

Read more →

Youtube Subscribe

---